IUCT Oncopole – Institut Universitaire du Cancer de Toulouse
Toulouse's cancer campus, joining the Institut Claudius Regaud and the university hospital, and a world leader in multiple myeloma research.
The IUCT Oncopole opened in 2014 on the site of the former AZF chemical plant, combining the Institut Claudius Regaud (a UNICANCER centre founded in 1923) with the oncology services of the CHU de Toulouse, next to the Cancer Research Center of Toulouse (CRCT) and Pierre Fabre's research centre. Its haematology group (Michel Attal, Hervé Avet-Loiseau) anchors the Intergroupe Francophone du Myélome, whose trials established transplant, lenalidomide maintenance and minimal residual disease as pillars of myeloma care. Other strengths are melanoma, gynaecological and head and neck cancers, radiotherapy and an early-phase unit. Patients from Occitanie access molecular tumour boards, CAR-T and bispecifics through the site.
- Multiple myeloma (IFM)
- Early-phase trials
- Melanoma
- Radiotherapy
- Cancer Research Center of Toulouse
Pages like this
not linked directly; found by shared links- IdeaOutcome-based annuity payments for potentially curative one-time therapies
Shares Ciltacabtagene autoleucel, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Multiple myeloma.
- InstitutionComprehensive Cancer Center Mainfranken, University Hospital Würzburg
Shares Ciltacabtagene autoleucel, Teclistamab, Bispecific antibodies, Multiple myeloma.
- InstitutionCentre Antoine Lacassagne
Shares UNICANCER, IMRT / IGRT (modern external beam), Head and neck squamous cell carcinoma, Melanoma.
- TrialCARTITUDE-1
Shares Ciltacabtagene autoleucel, Multiple myeloma, CAR-T cell therapy.
- InstitutionCancer Center Clínica Universidad de Navarra / CIMA
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Multiple myeloma, CAR-T cell therapy.
- InstitutionCentre Oscar Lambret
Shares UNICANCER, IMRT / IGRT (modern external beam), Cervical cancer, Head and neck squamous cell carcinoma.
- InstitutionIRCCS Azienda Ospedaliero-Universitaria di Bologna – Policlinico Sant'Orsola
Shares Teclistamab, Bispecific antibodies, Multiple myeloma, CAR-T cell therapy.
- IdeaOne CAR-T infusion instead of autologous transplant
Shares Ciltacabtagene autoleucel, Multiple myeloma, CAR-T cell therapy.